T2 Biosystems

T2 Biosystems is a technology company.

Active

Updated: Feb 17, 2026 ·

Recent News & Mentions

Mar 1, 2013FundingT2 Biosystems - Series E Aug 1, 2011FundingT2 Biosystems - Series D May 1, 2010FundingT2 Biosystems - Series C Oct 1, 2008FundingT2 Biosystems - Series B Dec 1, 2005FundingT2 Biosystems - Series A

Financial History

T2 Biosystems has raised $95.0M across 5 funding rounds. Most recently, it raised $40.0M Series E in March 2013.

Total Raised

$95.0M

Valuation

N/A

Funding Rounds Raised

Date	Round	Other Investors
Mar 1, 2013	$40.0M Series E	Aisling Capital, Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Versant Ventures, Jason Henrichs
Aug 1, 2011	$23.0M Series D	Aisling Capital, Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Versant Ventures, Jason Henrichs
May 1, 2010	$15.0M Series C	Aisling Capital, Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Versant Ventures, Jason Henrichs
Oct 1, 2008	$11.0M Series B	Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Polaris Partners, Versant Ventures, Jason Henrichs
Dec 1, 2005	$6.0M Series A	Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Polaris Partners, Versant Ventures, Jason Henrichs

Financial History

T2 Biosystems has raised $95.0M across 5 funding rounds.

Total Raised

$95.0M

Valuation

N/A

Deep Dive

High-Level Overview

T2 Biosystems (NASDAQ: TTOO) is a medical technology company developing rapid diagnostic products for sepsis-causing pathogens and antibiotic resistance, using proprietary T2 Magnetic Resonance (T2MR) technology to detect infections directly from blood in 3-5 hours.[1][2][4] Its core products include the T2Dx Instrument platform, T2Bacteria Panel (detects 5+ bacterial pathogens), T2Candida Panel (identifies Candida species), T2Resistance Panel, and emerging tests like T2Lyme and T2Biothreat, serving hospitals, clinical labs, and research institutions to reduce diagnosis time from days to hours, improve patient outcomes, lower mortality, and cut healthcare costs.[1][2][4][5] The company targets sepsis—a leading hospital killer—with recent growth via FDA clearances for expanded panels, exclusive U.S. distribution with Cardinal Health, and partnerships like CARB-X and Prxcision for AI integration.[4][5][6]

Origin Story

Founded in 2006 and incorporated in Delaware, T2 Biosystems emerged from Flagship Pioneering to address unmet needs in rapid diagnostics, starting with sepsis detection using innovative T2MR technology that identifies pathogens without culturing.[1][2] Headquartered in Lexington, Massachusetts, the company built early traction through products like the T2Dx Instrument and panels for bacteria and Candida, gaining FDA clearances and CE Mark for Europe in 2017.[2][4] Pivotal moments include partnerships with CARB-X for resistance gene tests, studies validating Lyme detection in blood, and leadership hires like CFO Darlene Deptula-Hicks, evolving from R&D focus (e.g., $22.1M expenses in 2023 with ~90 employees) to commercialization amid a ~$16-20M market cap as of early 2024.[1][2][5]

Core Differentiators

T2MR Technology: Proprietary magnetic resonance platform enables culture-independent, direct-from-blood detection of pathogens and resistance in hours, outperforming traditional methods that take days.[1][2][4][5]
FDA-Cleared Products: Only cleared direct-from-blood tests for sepsis pathogens (T2Bacteria, T2Candida); recent expansions include Acinetobacter baumannii and pediatric use, plus Breakthrough Device designations for T2Resistance, T2Lyme, and Candida auris.[4]
Proven Clinical Impact: Reduces time to effective treatment, shortens ICU/hospital stays, cuts unnecessary antifungals, and saves costs—hospital data shows millions in savings.[2][4][5]
Strategic Partnerships: Exclusive Cardinal Health deal for U.S. sales, Vizient extension through 2026, Prxcision AI co-marketing, and CARB-X funding accelerate adoption and pipeline.[4][5][6]

Role in the Broader Tech Landscape

T2 Biosystems rides the sepsis and antimicrobial resistance (AMR) crisis, where delayed diagnosis contributes to 11M annual global deaths and escalating hospital costs, amplified by post-COVID infection surges.[4][5] Timing aligns with FDA priorities for rapid diagnostics and U.S. government initiatives like BARDA/ASPR funding via CARB-X, positioning T2 to influence precision medicine by enabling faster, targeted therapies over broad-spectrum antibiotics.[5] In the medtech ecosystem, it counters AMR through direct detection, supports antibiotic trials, and integrates with AI platforms, fostering hospital efficiency amid trends like value-based care and biothreat preparedness.[4][5][6]

Quick Take & Future Outlook

T2 Biosystems is poised for acceleration in 2025 with pipeline advancements (e.g., T2Resistance commercialization, Lyme panel), strengthened distribution via Cardinal/Vizient, and AI synergies to drive product sales amid AMR urgency.[4][6] Rising sepsis prevalence, regulatory tailwinds, and cost-saving proofs will shape growth, potentially expanding influence in global diagnostics if execution scales beyond current microcap status. This rapid-detection pioneer could redefine sepsis care, tying back to its mission of saving lives through faster, smarter treatment.[1][3][4]

Sources

Frequently Asked Questions

How much funding has T2 Biosystems raised?

T2 Biosystems has raised $95.0M in total across 5 funding rounds.

Who are T2 Biosystems's investors?

T2 Biosystems's investors include Aisling Capital, Ascension Ventures, EQT Life Sciences, Flagship Pioneering, Flare Capital Partners, Johnson & Johnson Innovation, Polaris Partners, Versant Ventures, Jason Henrichs.